CLN-978: The Future of Lupus, Rheumatoid Arthritis, and Sjögren’s Disease Treatment скачать в хорошем качестве

CLN-978: The Future of Lupus, Rheumatoid Arthritis, and Sjögren’s Disease Treatment

Autoimmune conditions like lupus, rheumatoid arthritis, and Sjögren’s disease affect millions of people around the world. Even with available treatments, many patients continue to face persistent symptoms and long-term challenges. In this video, Dr. Jeff Jones, Chief Medical Officer at Cullinan Therapeutics, introduces CLN-978, a therapy with the potential to change how we treat autoimmune conditions like lupus, rheumatoid arthritis, and Sjögren’s disease. This investigational therapy is called a T cell engager and is designed to precisely target and remove abnormal B cells that drive autoimmune activity. By resetting the immune system rather than broadly suppressing it, CLN-978 has the potential to transform how autoimmune diseases are treated. You’ll learn: • What CLN-978 is and how it works • How it differs from existing therapies, including CAR-T treatments • How CLN-978 is designed to be an “off-the-shelf” therapy delivered through a simple subcutaneous (under-the-skin) injection A new investigational therapy. A step forward in autoimmune research. To learn more about CLN-978, visit: https://linktr.ee/cln978 This program was made possible with support from Cullinan Therapeutics.